Cognition Research Study – Now Under Way

Thank you for the great response. We are no longer accepting new referrals. We expect to complete the study in Spring 2010.

Juvenon's clinical trial will assess the effects of our formulation on cognitive performance of healthy older subjects who are experiencing age-associated cognitive decline.

Cognitive Decline with Age

Literally thousands of studies in humans and animals have shown that learning and memory abilities decline progressively, and often markedly, after the organism reaches maturity and passes into later stages of its lifespan. The magnitude of decline in humans depends upon the demands of the test administered. For example, on tests related to critical tasks of daily life, such as recalling the names of persons to whom one is introduced, the decline between ages 25 and 75 exceeds 50%, even when older subjects with common medical problems that can impair memory are excluded from the comparison. Declines of a similar magnitude have been reported on numerous tasks that are critical in daily life. Thus, although memory loss in later life may be “normal,” it may also be highly problematic.

	Principal Investigator Thomas H. Crook III, Ph.D., is a clinical psychologist with more than 30 years’ experience in research related to the diagnosis, assessment, and treatment of adult-onset cognitive disorders. Dr. Crook has served as a consultant to pharmaceutical companies and to governmental agencies and has been Principal Investigator on several large studies related to the effects of drugs on cognition.

Study Objective

Juvenon scientists have demonstrated in peer-reviewed studies that the combination of ingredients in Juvenon Cellular Health Supplement enhanced the cognitive performance of laboratory animals (click here to see scientific article). The objective of the study, therefore, is to establish the effects of Juvenon™ Cellular Health Supplement on learning and memory among persons with Age-Associated Memory Impairment.

Study Methodology

This will be a double-blind, placebo controlled parallel study in which randomly selected subjects will receive the Juvenon product and others, also randomly selected, will take a placebo. A battery of well-validated neuropsychological tests will be administered to assess a variety of brain functions, including visual recall, reaction time, and learning. The study will be conducted by trained study coordinators via telephone. This modality will allow a larger number of participants than would be possible in a site-based study; therefore enrollment will not be confined to any one particular geographic area.

Approximately 180 volunteers – men and women between the ages of 50 and 79 – will be enrolled. Each subject will take tablets twice a day for 12 weeks. At the outset of the study, and several times after that, participants will be administered a series of tests by trained study coordinators via telephone. Individual test results will be available to participants upon completion of the study.

Participant Selection Process

Persons participating in the study were asked to answer a series of screening questions. Final selection was performed under the supervision of a medical monitor. Recruitment of participants for the study is now complete.

Technical Considerations

The study is being performed by Cognitive Research Corp. (CogRes), a contract research organization specialized in conducting clinical trials of treatments for cognitive deficits, including those that occur in the course of "normal" aging.